- Pyridine and Pyrazine derivative for the Treatment of CF, COPD, and Bronchiectasis
-
The present invention provides pyridine and pyrazine derivatives which restore or enhance the function of mutant and/or wild type CFTR to treat bronchiectasis, cystic fibrosis, primary ciliary dyskinesia, chronic bronchitis, chronic obstructive pulmonary disease, asthma, respiratory tract infections, lung carcinoma, xerostomia and keratoconjunctivitis sire, or constipation (IBS, IBD, opioid induced). Pharmaceutical compositions comprising such derivatives are also encompassed.
- -
-
Paragraph 0583
(2020/12/18)
-
- Pyridine derivative PIM kinase inhibitor and preparation method therefor and application thereof in pharmacy
-
The present invention provides a PIM kinase inhibitor and a preparation method therefor and an application thereof. The PIM kinase inhibitor is a compound with the structural formula shown in the formula I (the formula is shown in description). The present invention further provides a stereoisomer, a tautomer and pharmaceutical salt of the compound shown in the formula I. According to the present invention, the compound has an obvious inhibition effect on kinase activity. The PIM kinase inhibitor can be used for preparing drugs for curing or preventing cancer, autoimmune diseases, allergic reaction diseases or organ transplant rejection resistance and the like, and the PIM kinase inhibitor has relatively large value in clinical application.
- -
-
Paragraph 0191; 0192; 0193; 0194
(2016/10/07)
-
- HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF CYSTIC FIBROSIS
-
The present invention provides pyridin-oxadiazole/thiadiazole derivatives of Formula I wherein A is N or CR 4a; and (ii) or (iii) which restore or enhance the function of mutant and/or wild type CFTR to treat cystic fibrosis, primary ciliary dyskinesia, chronic bronchitis, chronic obstructive pulmonary disease, asthma, respiratory tract infections, lung carcinoma, xerostomia and keratoconjunctivitis sire, or constipation (IBS, IBD, opioid induced). Pharmaceutical compositions comprising such derivatives are also encompassed.
- -
-
Page/Page column 80; 81
(2013/03/28)
-
- PYRIDINE AMIDE DERIVATIVES
-
The present invention provides pyridine derivatives which restore or enhance the function of mutant and/or wild type CFTR to treat cystic fibrosis, primary ciliary dyskinesia, chronic bronchitis, chronic obstructive pulmonary disease, asthma, respiratory
- -
-
Page/Page column 52
(2013/03/28)
-
- Pyridine amide derivatives
-
The present invention provides pyridine amide derivatives which re? store or enhance the function of mutant and/or wild type CFTR to treat cystic fibrosis, primary ciliary dyskinesia, chronic bronchitis, chronic obstructive pulmonary disease, asthma, resp
- -
-
Page/Page column 48
(2013/03/28)
-
- PYRIDINE/PYRAZINE AMIDE DERIVATIVES
-
The present invention provides pyridine/pyrazine amide derivatives which restore or enhance the function of mutant and/or wild type CFTR to treat cystic fibrosis, primary ciliary dyskinesia, chronic bronchitis, chronic obstructive pulmonary disease, asthm
- -
-
Page/Page column 50
(2013/03/28)
-
- N-SUBSTITUTED HETEROCYCLYL CARBOXAMIDES
-
A compound of Formula I and pharmaceutically acceptable salts and solvates thereof, wherein R1, R2, R3, Ra, A, B, D and E are all as defined herein. The compounds modulate the activity of CFTR and are useful in
- -
-
Page/Page column 62
(2013/03/28)
-
- Pyridine and Pyrazine derivative for the Treatment of CF
-
The present invention provides pyridine and pyrazine derivatives which restore or enhance the function of mutant and/or wild type CFTR to treat cystic fibrosis, primary ciliary dyskinesia, chronic bronchitis, chronic obstructive pulmonary disease, asthma, respiratory tract infections, lung carcinoma, xerostomia and keratoconjunctivitis sire, or constipation (IBS, IBD, opioid induced). Pharmaceutical compositions comprising such derivatives are also encompassed.
- -
-
Page/Page column 32
(2011/10/10)
-